foxo4-dri human trials results 2022 Lupus Highlight FOXO4-DRI alleviates RIPF. (A) Representative
Description
Not sure which one fits
Conover CA, Lee PD, Kanaley JA, Clarkson JT, Jensen MD
doi: 10.5604/17322693.1150133 26 LuoMZhaoFChengHSuMWangY
Be careful when disposing of needles to avoid any accidents
The dosing landscape for AOD-9604 is genuinely ambiguous because the clinical trials used oral delivery (the compound shows reasonable oral bioavailability, which is unusual for peptides) while most current research applications use subcutaneous injection
